- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06482853
Efeitos cardiovasculares da angiotensina-(1-7) na hipertensão por obesidade
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
A randomized, double blind, placebo controlled, crossover study will be conducted to determine if acute intravenous angiotensin-(1-7) infusion reduces cardiovascular sympathetic tone and blood pressure and improves the function of blood vessels in participants with obesity hypertension. This is an outpatient study that requires a screening visit, and if eligible, two study visits separated by at least one week in the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples collected at baseline and at the end of infusion. Blood pressure, heart rate, and muscle sympathetic nerve activity (via microneurography) will be measured continuously throughout the study. Each study visit will last approximately 4 hours.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase inicial 1
Contactos e Locais
Contato de estudo
- Nome: Aimee Cauffman, RN
- Número de telefone: 717-531-1617
- E-mail: acauffman@pennstatehealth.psu.edu
Estude backup de contato
- Nome: Amy Arnold, PhD
- Número de telefone: 717-531-3674
- E-mail: aarnold5@pennstatehealth.psu.edu
Locais de estudo
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Recrutamento
- Penn State Milton S. Hershey Medical Center
-
Subinvestigador:
- Urs A Leuenberger, MD
-
Subinvestigador:
- Aimee Cauffman, RN
-
Subinvestigador:
- Cheryl Blaha, RN
-
Subinvestigador:
- Jian Cui, PhD
-
Contato:
- Amy Arnold, PhD
- Número de telefone: 717-531-3674
- E-mail: aarnold5@pennstatehealth.psu.edu
-
Subinvestigador:
- Takuto Hamaoka, MD, PhD
-
Subinvestigador:
- Mami Hamaoka, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men and women of all races
- Age 18 to 65 years
- Body mass index (BMI) between 30-45 kg/m2
- Pre-hypertension (defined as two or more seated blood pressure readings >120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings >130/80 mmHg or use of antihypertensive medications)
- Capable of giving informed consent
- Fluent in written and spoken English
- Satisfactory history and physical exam
Exclusion Criteria:
- Age ≤ 17 or ≥ 66 years
- Taking more than two antihypertensive medications
- Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)
- Pregnant or nursing women
- Women taking hormone replacement therapy within 6 months
- Decisional impairment
- Prisoners
- Alcohol or drug abuse
- Current smokers
- Highly trained athletes
- Subjects with >5% weight change in the past 3 months
- BMI > 45 kg/m2
- Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)
- History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack)
- History or presence of immunological or hematological disorders
- Impaired hepatic function [aspartate aminotransferase (AST) or alanine transaminase (ALT) levels >2 times upper limit of normal range]
- Impaired renal function (serum creatinine >2.0 mg/dl)
- Anemia
- Treatment with drugs increasing sympathetic activity [e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants]
- Treatment with phosphodiesterase-5 inhibitors
- Treatment with anticoagulants (e.g. warfarin)
- Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month)
- Treatment with any investigational drug in the 1-month preceding the study
- Inability to give, or withdraw, informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Angiotensin-(1-7)
Participants will receive intravenous angiotensin-(1-7) at one study visit for a total of 120 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following this 30 minute dose escalation period, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 90 minutes. Infusion rates will be calculated for each patient based on body mass. |
This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Outros nomes:
|
|
Comparador de Placebo: Saline
Participants receive intravenous saline at one study visit for a total of 120 minutes. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. |
Saline will be used as the placebo comparator.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Burst Rate
Prazo: 120 minutes
|
Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Brachial Artery Diameter
Prazo: 120 minutes
|
A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Burst Incidence
Prazo: 120 minutes
|
Muscle sympathetic nerve burst incidence will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Muscle Sympathetic Nerve Amplitude
Prazo: 120 minutes
|
Muscle sympathetic nerve amplitude will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Muscle Sympathetic Nerve Total Activity
Prazo: 120 minutes
|
Muscle sympathetic nerve total activity will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Systolic Blood Pressure
Prazo: 120 minutes
|
Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Diastolic Blood Pressure
Prazo: 120 minutes
|
Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Heart Rate
Prazo: 120 minutes
|
Heart rate will be measured continuously by electrocardiogram during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Plasma Catecholamines
Prazo: 120 minutes
|
Circulating catecholamine levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Angiotensin II
Prazo: 120 minutes
|
Plasma angiotensin II levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Angiotensin-(1-7)
Prazo: 120 minutes
|
Plasma angiotensin-(1-7) levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Renin Activity
Prazo: 120 minutes
|
Plasma renin activity will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Aldosterone
Prazo: 120 minutes
|
Plasma or serum aldosterone levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Heart Rate Variability
Prazo: 120 minutes
|
Heart rate variability will be calculated from the continuous electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Baroreflex Sensitivity
Prazo: 120 minutes
|
Baroreflex sensitivity will be calculated from the continuous blood pressure and electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Amy Arnold, PhD, Pennsylvania State University College of Medicine
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Distúrbios Nutricionais
- Supernutrição
- Peso corporal
- Excesso de peso
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Obesidade
- Hipertensão
- Produtos químicos orgânicos
- Preparações farmacêuticas
- Ácidos graxos
- Lipídios
- Ácidos, acíclico
- Ácidos carboxílicos
- Produtos químicos inorgânicos
- Compostos de cloro
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Ácidos graxos, voláteis
- Compostos de sódio
- Cloretos
- Ácido clorídrico
- Solução salina
- Cloreto de sódio
- Acetatos
- Angiotensina I (1-7)
Outros números de identificação do estudo
- STUDY 8170-Part 2
- R01HL170140 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be available to other researchers.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .